Key result
A single injection of the novel MPL agonist antibody 2R13 promoted megakaryocyte maturation and sustained higher platelet counts than recombinant human TPO in a mouse model of chemotherapy-induced thrombocytopenia.
Why the study?
No MPL agonists have been approved for managing chemotherapy-induced thrombocytopenia due to efficacy or safety concerns, necessitating the development of effective new agents.
Population
8- to 10-week-old wild-type BALB/c female mice and 5-fluorouracil-induced thrombocytopenic mice
Comparison
Single injection of 2R13 vs seven consecutive days of rhTPO
Design
Preclinical in vitro and in vivo animal study
Follow-up
14 days
Authors
Loading...
Should not yet change practice in chemotherapy-induced thrombocytopenia; leaves open human confirmation of 2R13 versus TPO.
The novel human anti-MPL agonist antibody 2R13 effectively promotes megakaryopoiesis and platelet production in vivo, suggesting potential as a therapeutic agent for chemotherapy-induced thrombocytopenia.
Shin et al. (2022) studied Chemotherapy-induced thrombocytopenia. 2R13 (anti-MPL agonist antibody) vs. Recombinant human TPO (rhTPO) or vehicle control was evaluated on Platelet count recovery and megakaryocyte differentiation. A single injection of the novel MPL agonist antibody 2R13 promoted megakaryocyte maturation and sustained higher platelet counts than recombinant human TPO in a mouse model of chemotherapy-induced thrombocytopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: